Search Articles — Sudonull

https://sudonull.com/owasp-top-10-explained-what-it-is-why-it-matters

Learn what is the OWASP Top 10 and why does it matter for secure coding. A developer's guide to web app vulnerabilities, risks, and practical defense strategies.

https://sudonull.com/split-keyboard-vs-rsi-effectiveness-analysis-ergonomics

When a split keyboard solves the RSI problem for developers, and when it is powerless? Detailed breakdown of anatomical factors, adaptation stages, and application limits. Practical recommendations.

https://sudonull.com/perceptual-hash-search-for-similar-images

How perceptual hashing algorithms work: from simple averaging to DCT. Comparison of methods and practical application for developers.

https://sudonull.com/llm-dialog-creating-a-go-utility-for-comparing-language-models

Development of a Graphical Utility in Go for Automating Dialog Between Language Models. LLM Comparison, Context Management, Practical Application for Developers.

https://sudonull.com/npu-on-mcu-for-speech-stm32n6-and-acoustics

Acoustic speech recognition model on STM32N6 with NPU: PER 5.3%, 0.2 W, real time. Comparison, metrics, application for developers. Study the implementation.

https://ymaho.com/pediatric-dovato-ema-approves-application-for-hiv-therapy

EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.

https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

https://ymaho.com/pediatric-dovato-viiv-application-and-geopolitics-of-the-hiv-market

ViiV has submitted applications to the FDA and EMA for dispersible Dovato tablets for children. We analyze the strategy, patents, and implications. Find out who will win.

https://ymaho.com/study-of-the-ottava-robot-forte-results-and-fda-application

Scientists have completed the pivotal study of the Ottava robot (FORTE) and are preparing an FDA application. Learn about clinical data, zero conversions, and market prospects for robotic surgery.

https://ymaho.com/gene-therapy-for-deafness-otarmeni-ema-accelerated-review-2026

EMA accepted the application for gene therapy otarmeni for the treatment of hereditary deafness OTOF. Market analysis, forecasts, price and implications for the industry. Read.

https://ymaho.com/spacex-ipo-filing-for-75-billion-and-valuation-of-1-75-trillion

SpaceX filed an application for the largest IPO in history on Nasdaq up to $75 billion. Valuation $1.75 trillion, listing in June 2026. Analysis of the record, consequences and hidden details. Read more.

https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.

https://lrivo.com/linlithgow-rose-spfl-play-off-exclusion-due-to-licence

Linlithgow Rose miss SPFL play-offs after SFA bronze licence application declined. Brora Rangers face Edinburgh City in final. Learn why.

https://ymaho.com/ai-for-early-diagnosis-of-gallbladder-cancer-accuracy-92-97

PGIMER AI model analyzes ultrasound and detects gallbladder cancer at an early stage. Free application for hospitals. Data from The Lancet. Learn more.

https://ymaho.com/ipo-of-uznif-uzbekistan-s-entry-onto-the-london-stock-exchange-for-1-95-billion

Dual IPO of Uzbekistan's National Fund for $1.95 billion in Tashkent and London. GDR price — $25. Submit your application by May 12 and learn the placement details.